Related Experiment Videos
CHRONIC MYELOID LEUKAEMIA WITH LYMPHOSARCOMA.
Journal of Clinical Pathology
|September 1, 1963
Summary
Two patients with chronic myeloid leukemia treated with busulfan developed lymphosarcoma. Busulfan appeared to control leukemia effectively despite the secondary cancer diagnosis.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Secondary malignancies can occur in patients with hematologic disorders.
- Busulfan is a chemotherapy agent used in CML treatment.
Purpose of the Study:
- To describe the clinical and pathological features of two CML patients who developed lymphosarcoma.
- To evaluate the efficacy of busulfan in controlling CML in the context of secondary lymphosarcoma development.
Main Methods:
- Case report of two patients.
- Review of clinical and pathological data.
- Analysis of treatment response to busulfan.
Main Results:
- Two patients with chronic myeloid leukemia were diagnosed with lymphosarcoma.
- Busulfan therapy was ongoing and appeared to be effectively managing the leukemia in both cases at the time of lymphosarcoma diagnosis and death.
- Autopsy findings confirmed both conditions.
Conclusions:
- Busulfan may not prevent the development of secondary lymphosarcoma in chronic myeloid leukemia patients.
- Further research is needed to understand the relationship between busulfan therapy, CML, and secondary malignancies.